Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

56
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

163
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
163
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

925
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
925
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

113
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
113
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

51
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
51
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

90
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
90

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Racial/ethnic differences in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for atherosclerotic cardiovascular disease (ASCVD) benefit in patients with type 2 diabetes.

Current medical research and opinion·2025
Same author

A Sex Comparison of Fall and Fracture Occurrence in the Elderly Diabetic Population: A Quantitative Study.

Women's health reports (New Rochelle, N.Y.)·2025
Same author

Two Is Better Than One: Clinical Assessments.

Journal of patient experience·2025
Same author

Idiopathic and Metabolic Triggers Leading to Recurrent Acute Pancreatitis in a 30-Year-Old Woman.

Hospital pharmacy·2025
Same author

Insight into pharmacy students' perspectives on mandatory COVID-19 vaccines in schools and healthcare settings.

Therapeutic advances in vaccines and immunotherapy·2024
Same author

Advancing Health Equity: A Collaborative Framework to Address HIV Disparities in Georgia and Louisiana through Data, Education, and Policy Initiatives.

Journal of health care for the poor and underserved·2024

Related Experiment Video

Updated: Oct 1, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns.

Fahamina Ahmed1, Shelby Gross2, Samah Hammad3

  • 1Clinical Assistant Professor, Division of Clinical and Administrative Sciences, Xavier University of Louisiana, New Orleans.

American Health & Drug Benefits
|March 9, 2022
PubMed
Summary

Statin prescribing for atherosclerotic cardiovascular disease (ASCVD) prevention differs between patients with diabetes and those with high LDL. Optimal statin use requires further investigation to address disparities in high-risk populations.

Keywords:
atherosclerotic cardiovascular diseasecardiovascular risk factorsdiabeteslow-density lipoproteinstatin prescribing patternsstatin treatment guidelines

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.1K

Related Experiment Videos

Last Updated: Oct 1, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.1K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacotherapy

Background:

  • 2018 guidelines emphasize individualized ASCVD prevention with risk-enhancing factors.
  • Disparities in statin prescribing patterns persist despite established benefits.

Purpose of the Study:

  • To assess optimal statin therapy use in high-risk populations for ASCVD primary prevention.
  • To compare statin use in patients with diabetes versus elevated low-density lipoprotein (LDL).
  • To analyze statin prescribing based on the number of ASCVD risk factors.

Main Methods:

  • Retrospective chart review of 262 patients eligible for statin therapy.
  • Groups: diabetes (A1c ≥6.5%) or elevated LDL (≥190 mg/dL).
  • Subgroups based on 10-year ASCVD risk: ≥7.5% and <7.5%.

Main Results:

  • Patients with diabetes and ≥7.5% ASCVD risk had the most risk factors.
  • Only 53.3% of high-risk diabetes patients received high-intensity statins.
  • Statin prescribing differed significantly: 70.6% for diabetes vs. 50% for elevated LDL (P=.002).

Conclusions:

  • Diabetes patients were more likely to receive statins than those with elevated LDL.
  • No significant difference in optimal statin therapy between the two groups.
  • Further research needed to identify barriers and improve statin use for ASCVD prevention.